Symptoms after Injectafer: low phosphate and who to call
The FDA tells people to report new or worsening symptoms after Injectafer immediately. Know what to tell the clinician and when a separate emergency response is needed.
Report new or worsening fatigue, muscle weakness or pain, bone or joint pain, or confusion after Injectafer to your healthcare provider immediately. The FDA boxed warning concerns symptomatic low phosphate with ferric carboxymaltose. A symptom alone does not distinguish low phosphate from anemia or another cause. Give the clinician the product name and what changed after the infusion.12
Report the change before trying to name its cause
Tell the clinician which symptoms were already present before the infusion and which are new or worse. Fatigue can be part of the anemia that led to treatment as well as a symptom the FDA flags. An appointment summary that says “iron infusion” does not identify the medicine. Use the brand or generic name from the visit record if you have it; if you do not, tell the clinician where the infusion took place so they can request the record.123
The FDA describes reports after a single exposure as well as after repeat treatment. Some reports involved bone complications. Reports are useful for detecting safety concerns, but they do not supply a complete denominator or predict what will happen after an individual infusion. A previous visit without a problem also does not answer how a new symptom should be assessed.12
Separate a lab result from a symptom report
The randomized FIRM analysis compared ferric carboxymaltose with ferumoxytol in adults with iron deficiency anemia. Low measured phosphate was substantially more frequent with ferric carboxymaltose in that trial. That comparison is stronger evidence of a difference between those two formulations than a count of voluntary reports. It measured phosphate in a defined group, however. Its laboratory frequency is not the frequency of symptomatic cases, fractures or events after every kind of IV iron.3
When you contact the clinician, describe the symptom and how it differs from the reason you sought care. Fatigue that persisted and weakness that appeared after an infusion both belong in the account. Neither symptom alone identifies the cause. The prescribing team can review which laboratory results it needs, what it already has and who should interpret a result if another clinician ordered it.12
| What you have | What it helps the team confirm |
|---|---|
| Infusion record | Which iron formulation was given and where the treatment is documented. |
| Prior results | What was measured and who can interpret the result in context. |
| New symptoms | Which changes need immediate contact with the healthcare provider. |
| Follow-up contact | Which clinician receives symptoms or results if the ordering and infusion teams differ. |
Give the next clinician enough information to act on the message
Name the infusion site and whether the clinician taking the call prescribed the treatment or is seeing you for a new concern. If you have more than one infusion record, identify which one lists ferric carboxymaltose and which symptoms were present before it. If the office says a result was normal, ask which result it means. An iron or anemia measure does not answer the same question as phosphate. A copy of the actual results is more useful than a general note that “the labs were checked.”123
The FDA describes reports in people without obvious risk factors, so the absence of a known risk factor should not be used to dismiss a new symptom. Tell the team if you are already being evaluated elsewhere so the infusion and prescribing records can be matched.12
Keep emergency reactions separate
Trouble breathing or loss of consciousness can signal a serious allergic reaction. Call 911 for signs of a serious allergic reaction, including difficulty breathing or loss of consciousness. The emergency handoff is separate from reporting a new symptom that might relate to phosphate. The iron infusion consultation guide covers what to ask about the medical setting. A general IV service listing does not establish that a practice offers IV iron or can provide the follow-up an individual needs.24
Sources
- U.S. Food and Drug Administration. FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels. September 2026 communication specifies the product, describes postmarketing reports and tells patients to report new or worsening symptoms immediately. Accessed .
- U.S. Food and Drug Administration. INJECTAFER (ferric carboxymaltose injection) prescribing information. August 2026 approved labeling and patient information describe symptomatic hypophosphatemia, follow-up responsibilities and hypersensitivity separately. Accessed .
- JCI Insight / original randomized analysis. Randomized trial of intravenous iron-induced hypophosphatemia. Full FIRM secondary analysis compares phosphate laboratory outcomes with ferric carboxymaltose and ferumoxytol. Accessed .
- MedlinePlus. Anaphylaxis. Supports emergency help for signs of a serious allergic reaction. Accessed .